LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Search

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

78.99 0.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

78

Max

79.78

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-252M

-129M

Pardavimai

-295M

157M

Pelnas, tenkantis vienai akcijai

-0.613

Pelno marža

-82.062

Darbuotojai

1,069

EBITDA

-245M

-94M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+7.95% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

1.6B

13B

Ankstesnė atidarymo kaina

78.47

Ankstesnė uždarymo kaina

78.99

Naujienos nuotaikos

By Acuity

34%

66%

118 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-11 23:58; UTC

Įsigijimai, susijungimai, perėmimai

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

2025-12-11 23:56; UTC

Uždarbis

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

2025-12-11 23:03; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

2025-12-11 22:06; UTC

Įsigijimai, susijungimai, perėmimai

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

2025-12-11 21:50; UTC

Uždarbis

Costco Same-Store Sales, Membership Fees Rose in 1Q

2025-12-11 23:45; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-11 23:44; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

2025-12-11 23:37; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

2025-12-11 23:31; UTC

Uždarbis

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

2025-12-11 22:48; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

2025-12-11 22:35; UTC

Uždarbis

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

2025-12-11 22:30; UTC

Uždarbis

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

2025-12-11 22:09; UTC

Įsigijimai, susijungimai, perėmimai

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

2025-12-11 22:06; UTC

Įsigijimai, susijungimai, perėmimai

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

2025-12-11 22:05; UTC

Uždarbis

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

2025-12-11 21:51; UTC

Įsigijimai, susijungimai, perėmimai

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

2025-12-11 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-11 21:39; UTC

Uždarbis

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

2025-12-11 21:39; UTC

Uždarbis

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

2025-12-11 21:38; UTC

Uždarbis

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

2025-12-11 21:37; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

2025-12-11 21:37; UTC

Rinkos pokalbiai

Broadcom Sees AI Revenue Doubling -- Market Talk

2025-12-11 21:34; UTC

Įsigijimai, susijungimai, perėmimai

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

2025-12-11 21:29; UTC

Įsigijimai, susijungimai, perėmimai

Dexus Aiming for Long-Term Holding of A$50M in Fund

2025-12-11 21:28; UTC

Rinkos pokalbiai

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

2025-12-11 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Dexus Expects to Introduce Additional Third-Party Equity in FY26

2025-12-11 21:28; UTC

Įsigijimai, susijungimai, perėmimai

Dexus: Third Party Investors to Contribute Remainder

2025-12-11 21:27; UTC

Įsigijimai, susijungimai, perėmimai

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

2025-12-11 21:26; UTC

Įsigijimai, susijungimai, perėmimai

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

2025-12-11 21:25; UTC

Įsigijimai, susijungimai, perėmimai

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

7.95% į viršų

12 mėnesių prognozė

Vidutinis 84.88 USD  7.95%

Aukščiausias 110 USD

Žemiausias 65 USD

Remiantis 18 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

18 ratings

15

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Neutral Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

118 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat